Sustainability at Biocon

Biocon 1 Financial Highlights: Q4FY22 Revenue Q4 FY22 Q4 FY21 +21% 2,476Cr * Core EBITDA* +37% *815Cr *594Cr % margin 33% 32% *2,048Cr Biosimilars +48% | Generics +26% | Research Services +15% Dilution Gain in Bicara of 30Cr vs 160Cr in Q4FY21 Mark-to-market loss on investments of *6Cr Forex Gain of 2Cr vs 7Cr in Q4FY21 EBITDA +3% *659Cr *641Cr Gross R&D spend at *232Cr R&D spend in P&L *191Cr % margin 27% 31% Profit Before Tax +9% *384Cr *353Cr before Exceptional Items % margin Exceptional Loss of *41Cr vs Gain of 13Cr in Q4FY21 15% 17% Net Profit 262Cr *257Cr Net Profit after exceptional items at *239Cr Before exceptional items % margin 11% 13% *Core EBITDA defined as EBITDA before forex, dilution gain in Bicara, R&D, mark-to-market loss on investments and licensing income

View entire presentation